FY2029 EPS Estimate for Moderna Lowered by Analyst

Moderna, Inc. (NASDAQ:MRNA) – Brookline Capital Markets lowered their FY2029 earnings per share estimates for Moderna in a research report issued on Friday, November 6th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings per share of $11.40 for the year, down from their prior estimate of $11.54. Brookline Capital Markets has a “Buy” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($6.11) per share. Brookline Capital Markets also issued estimates for Moderna’s FY2030 earnings at $18.03 EPS.

A number of other research analysts have also issued reports on the stock. Jefferies Financial Group reissued a “hold” rating and set a $150.00 target price (up from $60.00) on shares of Moderna in a research note on Wednesday, August 19th. Argus upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a research report on Friday, August 28th. Singular Research upgraded shares of Moderna to a “hold” rating in a research note on Wednesday, September 23rd. Rothschild & Co Redburn cut Moderna from a “neutral” rating to a “sell” rating and lifted their price target for the company from $40.00 to $81.00 in a report on Thursday, September 3rd. Finally, Loop Capital set a $135.00 price target on Moderna in a report on Wednesday, August 19th. Six research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, Moderna has a consensus rating of “Hold” and an average target price of $113.75.

Moderna Stock Up 5.8%

MRNA stock opened at $269.00 on Tuesday. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. Moderna has a fifty-two week low of $22.28 and a fifty-two week high of $280.80. The firm’s 50-day simple moving average is $194.47 and its 200 day simple moving average is $92.61. The stock has a market cap of $107.40 billion, a PE ratio of -37.89 and a beta of 1.16.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, November 6th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($1.10) by $1.48. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company’s quarterly revenue was up 29.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.51) earnings per share.

Institutional Trading of Moderna

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of Moderna in the second quarter valued at approximately $2,142,877,000. Theleme Partners LLP acquired a new position in shares of Moderna during the second quarter valued at approximately $564,272,000. Merck & Co. Inc. acquired a new position in shares of Moderna during the second quarter valued at approximately $161,642,545. Bamco Inc. NY acquired a new position in shares of Moderna during the second quarter valued at approximately $139,317,000. Finally, Bank of New York Mellon Corp bought a new stake in Moderna during the second quarter worth approximately $119,168,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Moderna

In related news, insider Shannon Klinger sold 3,471 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the transaction, the insider owned 74,129 shares in the company, valued at $10,374,353.55. This represents a 4.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 39,145 shares of the firm’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the transaction, the president directly owned 1,636,565 shares in the company, valued at approximately $361,222,626.80. The trade was a 2.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 197,251 shares of company stock worth $33,875,904 over the last ninety days. 10.80% of the stock is currently owned by corporate insiders.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Raised outlook and improved results: Moderna lifted its 2026 revenue-growth forecast to 15%–25% after a Q3 beat, citing lower costs and gains from respiratory vaccines. Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology
• Positive Sentiment: Oncology pipeline milestone: Phase 3 data for personalized cancer therapy intismeran showed a 42% reduction in melanoma recurrence or death risk. Moderna aims to file with the FDA by year-end 2026, potentially setting up a decision in 2027. Can Moderna’s First Cancer Therapy Win FDA Approval in 2027?
• Positive Sentiment: Moderna’s collaboration with Tempus AI is among partnerships expected to generate about $192.5 million over five years, adding a potential source of revenue beyond vaccine sales. The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
• Neutral Sentiment: Analysts raised one fair-value estimate from $135.84 to $145.42, reflecting improved Q3 execution and intismeran’s potential, while noting uncertainty about future COVID and oncology revenue. Moderna Stock Fair Value Rises After Intismeran Data And Q3 Beat
• Negative Sentiment: Revenue concentration and valuation risk: Nearly all revenue still comes from COVID-related products, leaving Moderna exposed to demand changes. Goldman Sachs raised its target to $195 but kept a neutral rating; that target and the cited fair-value estimate are both below the $269 price in the provided market data. Moderna’s Q3 Numbers May Have Seemed Impressive, but They Aren’t Enough to Make the Stock a Buy

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.